$1.20▾ 1.64%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Spero Therapeutics, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs